Liquidia Co. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 2,445 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the transaction, the insider now directly owns 267,943 shares in the company, valued at approximately $3,483,259. This trade represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Rajeev Saggar also recently made the following trade(s):
- On Tuesday, January 14th, Rajeev Saggar sold 6,249 shares of Liquidia stock. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22.
Liquidia Stock Performance
Shares of LQDA stock traded up $0.45 on Thursday, hitting $14.40. The stock had a trading volume of 1,260,826 shares, compared to its average volume of 966,916. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.99. The stock's 50 day moving average is $11.47 and its 200-day moving average is $11.06. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -8.83 and a beta of 0.23.
Institutional Investors Weigh In On Liquidia
Hedge funds have recently bought and sold shares of the business. Whitefort Capital Management LP increased its position in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock worth $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock valued at $3,903,000 after buying an additional 230,820 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after buying an additional 210,753 shares during the last quarter. Anson Funds Management LP acquired a new position in shares of Liquidia in the 3rd quarter worth approximately $1,764,000. Finally, Sapient Capital LLC bought a new stake in shares of Liquidia in the 3rd quarter valued at approximately $1,336,000. Institutional investors and hedge funds own 64.54% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on LQDA shares. Lifesci Capital started coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Scotiabank initiated coverage on Liquidia in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 target price on the stock. Wells Fargo & Company began coverage on Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, January 9th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Liquidia presently has a consensus rating of "Buy" and an average price target of $25.38.
Get Our Latest Report on LQDA
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
